Matthew Walls: Recognising CAD PRS as a New ‘Risk Enhancing Factor’ in the 2026 ACC/AHA Guidelines
Matthew Walls, Chief Executive Officer at GEN inCode, shared a post on LinkedIn:
“The updated 2026 ACC/AHA Dyslipidemia Guidelines were published on Friday representing the most significant update to U.S. cardiovascular risk assessment and lipid management over the past decade. Alongside the inclusion of the new prevent clinical risk equation and greater emphasis on treatment goals, from a genetic perspective we are delighted to see the new guidelines recognise an individual’s Coronary Artery Disease Polygenic Risk Score (‘CAD PRS’) as a new ‘risk enhancing factor’.
CAD PRS helps identify individuals in the population at higher risk to refine cardiovascular risk assessment. The adoption of genetics to enable ‘earlier in life’ cardiovascular risk assessment is compelling, particularly in younger adults or those with borderline/ intermediate clinical risk and as an aid to decision-making for earlier treatment e.g. statin initiation and/or to intensify lifestyle change and improved patient education to prevent CAD.
CAD PRS enables ‘earlier in life’ risk assessment and prevention of CAD through:
- Risk Reclassification: helps to up-classify individuals at borderline (3-<5%) or intermediate (5-<10%) clinical risk by identifying those who may be under diagnosed by standard clinical risk assessment tools.
- Younger adults: Helps identify individuals at higher lifetime risk who may need earlier lifestyle and/or pharmacological intervention e.g. statin treatment to reduce cholesterol.
- Family History application: CAD PRS is particularly useful for assessing individuals with limited family history or those with a low clinical risk but a strong family history of premature CAD, as the CAD PRS risk is additive to the clinical risk.
GENinCode and our partners have developed CARDIO inCode-Score (CAD PRS) and LIPID inCode tests over the past 15 years and have amassed a significant body of clinical evidence to support the utility of CAD PRS.
We would like to thank the authors, physicians and reviewers for their wisdom and support in promoting the inclusion of PRS in the new ACC/AHA guidelines.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series